Lyumjev is an ultra-rapid-acting mealtime insulin that begins working within 1 to 3 minutes of subcutaneous injection. It contains the same insulin lispro molecule as Humalog, formulated with treprostinil and citrate to speed absorption. Lyumjev is FDA-approved for adults with type 1 and type 2 diabetes and for continuous subcutaneous insulin infusion in pumps.
How Lyumjev Works
Insulin lispro-aabc is a reformulated version of the lispro molecule used in Humalog. Two excipients explain the ultra-rapid action: treprostinil, a prostacyclin analog that causes local vasodilation, and citrate, which increases vascular permeability. Together, they accelerate insulin absorption from the injection site, giving a faster, higher early peak than standard lispro.
The clinical goal is tighter control of the post-meal glucose surge — the “time above range” that contributes disproportionately to long-term complications. Like other mealtime insulins, Lyumjev is used with a separate basal insulin. For a broader look at how mealtime insulin fits into diabetes care, see the treatment overview.
Who Uses Lyumjev
Lyumjev is FDA-approved for adults with type 1 or type 2 diabetes who need mealtime insulin. It is commonly considered for:
- Patients with persistent post-meal glucose above 180 mg/dL despite accurate carb counting
- Insulin pump users seeking ultra-rapid action
- Those who eat before they can reliably inject — Lyumjev can be given within 20 minutes after the first bite
- People with gastroparesis or irregular eating patterns
Pediatric approval varies by product and jurisdiction; confirm with your care team and the current FDA label.
Onset, Peak, and Duration
| Insulin | Onset | Peak | Duration |
|---|---|---|---|
| Lyumjev (lispro-aabc) | 1 to 3 min | ~1 hr | 4 to 5 hr |
| Fiasp (faster aspart) | 2 to 4 min | ~1 hr | 3 to 5 hr |
| Humalog (lispro) | 10 to 15 min | 1 to 2 hr | 3 to 5 hr |
| Novolog (aspart) | 10 to 20 min | 1 to 3 hr | 3 to 5 hr |
| Regular human insulin | 30 to 60 min | 2 to 4 hr | 5 to 8 hr |
How Lyumjev Is Dosed
Dosing follows the same framework as other rapid analogs:
- Insulin-to-carb ratio — often 1 unit per 10 to 15 g of carbs for adults
- Correction factor — often 1 unit lowers glucose by 30 to 50 mg/dL
- Pre-meal target — typically 80 to 130 mg/dL
A common mealtime dose formula is: (carbs ÷ carb ratio) + ((current glucose − target) ÷ correction factor). Inject from 0 to 2 minutes before the meal or within 20 minutes after starting. If you are new to Lyumjev after using Humalog or another rapid analog, start with the same unit-for-unit dose, then fine-tune based on post-meal readings.
Clinical Trial Results
According to the PRONTO-T1D and PRONTO-T2D pivotal trials, Lyumjev achieved similar overall A1C reductions compared with Humalog but significantly lower 1-hour and 2-hour post-meal glucose. Rates of overall hypoglycemia were similar, though documented early post-meal hypoglycemia rates were slightly higher with Lyumjev in some analyses — a mirror of its faster onset.
For a primer on how A1C connects to your long-term health, see the A1C levels guide.
Common Side Effects
- Hypoglycemia (most common)
- Injection-site reactions — redness, swelling, stinging (more common than with Humalog)
- Lipohypertrophy with repeated same-site injection
- Weight gain
- Rare allergic reactions
Serious Warnings
Hypoglycemia
Ultra-rapid onset means severe hypoglycemia can occur sooner than with Humalog if a meal is delayed or skipped. Always carry glucose tablets or gel, and make sure family members know how to administer nasal (Baqsimi) or injectable (Gvoke HypoPen) glucagon.
Hypokalemia
Insulin shifts potassium into cells and can lower serum potassium. Higher risk in patients with kidney disease, on diuretics, or with baseline hypokalemia.
Fluid Retention
Combining Lyumjev with a thiazolidinedione such as pioglitazone raises the risk of fluid overload and heart failure.
Hypersensitivity
Severe allergic reactions are rare but possible. Stop Lyumjev and seek emergency care for widespread rash, facial swelling, difficulty breathing, or rapid heartbeat after injection.
Drug Interactions
Beta-blockers can mask early hypoglycemia signs. Corticosteroids, atypical antipsychotics, and high-dose thiazide diuretics can blunt insulin effect. Alcohol can prolong hypoglycemia. Keep an updated medication list.
Available Formulations
| Product | Concentration | Delivery |
|---|---|---|
| Lyumjev 10 mL vial | 100 units/mL | Syringe or pump |
| Lyumjev KwikPen U-100 | 100 units/mL | Prefilled disposable pen, 1-unit steps |
| Lyumjev KwikPen U-200 | 200 units/mL | Prefilled pen for high-dose users |
| Lyumjev Junior KwikPen | 100 units/mL, 0.5-unit steps | Pediatric and insulin-sensitive users (where available) |
Using Lyumjev in an Insulin Pump
Lyumjev is FDA-approved for continuous subcutaneous insulin infusion. Practical notes:
- Change infusion sets every 2 to 3 days
- Watch for occlusion alarms and unexplained glucose rises
- Rotate sites to prevent scar tissue
- Keep a back-up long-acting insulin pen in case of pump failure
Storage and Handling
- Unopened: refrigerate at 36 to 46 degrees Fahrenheit until expiration date
- In-use: room temperature below 86 degrees for up to 28 days, then discard
- Never freeze; protect from direct sunlight and heat
- Inspect before use — Lyumjev is clear and colorless; discard if cloudy or particulate
Cost and Coverage
Lyumjev is typically priced similar to Humalog and the authorized generic Insulin Lispro. Coverage details:
- Commercial insurance: most plans cover Lyumjev, often at the same tier as Humalog
- Lilly Insulin Value Program: caps cost at $35 per month for eligible patients
- Medicare Part D: $35-per-month cap under the Inflation Reduction Act
- Uninsured patients: may qualify for Lilly’s patient assistance program
Lyumjev vs. Fiasp
Lyumjev and Fiasp are the two ultra-rapid mealtime insulins in the United States. Both launch insulin into circulation within minutes and cut post-meal glucose peaks more than standard analogs. Head-to-head trials are limited, but clinical effects on post-meal glucose and A1C are broadly similar. Choice often depends on insurance coverage, pump compatibility, and individual tolerance — some users report stinging with Lyumjev, others with Fiasp.
When to Contact Your Care Team
- Severe hypoglycemia or loss of consciousness
- Repeated glucose above 250 mg/dL
- Positive urine ketones, vomiting, or inability to hold down fluids
- Persistent stinging or lumps at injection sites
- New medications, pregnancy plans, or surgery scheduling
- Suspected allergic reaction
Lifestyle Still Matters
Ultra-rapid insulin helps flatten post-meal glucose, but carbohydrate quality, meal timing, sleep, and activity drive long-term outcomes. The CDC reports that structured lifestyle programs can reduce progression from prediabetes to type 2 diabetes by 58 percent in adults at high risk — a benefit no medication matches on its own.
The Bottom Line
Lyumjev is a fast-acting mealtime insulin designed for tighter post-meal glucose control in adults with type 1 and type 2 diabetes. It offers a small, consistent advantage over Humalog at the 1- and 2-hour post-meal marks, with a similar overall A1C effect and a broadly similar safety profile. The main trade-offs are occasional injection-site stinging and the same hypoglycemia risk that accompanies any mealtime insulin. Ask your clinician whether Lyumjev fits your insulin plan, pump setup, and insurance coverage.
